As we enter the era of biosimilars in retina, Clinical Minute: Retina host Ramin Tadayoni, MD, PhD, invites Prof. Frank Holz to update viewers on the state of biosimilars in retina. Together, they will discuss what biosimilars are, how they are approved, whether they might offer cost savings to healthcare systems, and which markets might be best suited for rapid biosimilar adoption.
View video on Eyetube here.
Facebook Comments